Inhibitors of tankyrases (the selective inhibitor STP1002 and the dual PARP1/PARP2 and TNKS1/TNKS2 inhibitor E7449), PARP7 (RBN-2397), and PARP14 (RBN-31430) are currently undergoing clinical trials for treatment of cancer and inflammatory diseases.157. This evidence concerns the gene PARP14 and cancer.